• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Revvity Inc.

    3/12/25 8:05:23 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    DEFA14A 1 d925831ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒       Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    Revvity, Inc.

    (Name of Registrant as Specified in its Charter)

    Not applicable.

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒   No fee required.
    ☐   Fee paid previously with preliminary materials.
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

                    
                         
       

     

    Your Vote Counts!

          

           LOGO

     

    REVVITY, INC.

     

    77 4TH AVENUE

    WALTHAM, MA 02451

     

     

    REVVITY, INC.

     

    2025 Annual Meeting

    Vote by April 21, 2025 11:59 PM ET. For shares held in a

    Plan, vote by April 17, 2025 11:59 PM ET.

     

         
       
      LOGO       
       
       
         
         

     

         
     
     
         
     
         

    V62071-P24552-Z89246

                  
               

    You invested in REVVITY, INC. and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on April 22, 2025.

    Get informed before you vote

    View the Notice and Proxy Statement and Annual Report OR you can receive a free paper or email copy of the material(s) by requesting prior to April 8, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

    LOGO

     

     

    *Please check the meeting materials for any special requirements for meeting attendance.


    Vote at www.ProxyVote.com

     

     

    THIS IS NOT A VOTABLE BALLOT

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

     

     Voting Items  

    Board

    Recommends

     

    1.

     

    To elect ten nominees for director for terms of one year each:

     

    Nominees:

     

         
     

    1a.

      Peter Barrett, PhD   LOGO   For
     

    1b.

      Samuel R. Chapin   LOGO   For
     

    1c.

      Michael A. Klobuchar   LOGO   For
     

    1d.

      Michelle McMurry-Heath, MD, PhD   LOGO   For
     

    1e.

      Alexis P. Michas   LOGO   For
     

    1f.

      Prahlad R. Singh, PhD   LOGO   For
     

    1g.

      Sophie V. Vandebroek, PhD   LOGO   For
     

    1h.

      Michel Vounatsos   LOGO   For
     

    1i.

      Frank Witney, PhD   LOGO   For
     

    1j.

      Pascale Witz   LOGO   For
     

    2.

      To ratify the selection of Deloitte & Touche LLP as Revvity’s independent registered public accounting firm for the current fiscal year.   LOGO   For
     

    3.

      To approve, by non-binding advisory vote, our executive compensation.   LOGO   For
     

    4.

      To approve amendments to Revvity’s Restated Articles of Organization, as amended, and Amended and Restated By- laws to implement a majority voting standard for specified corporate actions.   LOGO   For
     

    5.

      To approve the shareholder proposal regarding ability to call a special shareholder meeting, if properly presented at the annual meeting.   LOGO   Against

    NOTE: The proxies are authorized to vote, in their discretion, upon such other business as may properly come before the meeting or any adjournment or postponement thereof.

         

     

    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

     

    V62072-P24552-Z89246           

    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity to Hold Earnings Call on Monday, October 27, 2025

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workfl

    10/6/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

    New software further strengthens Revvity's market-leading position in in vivo imaging while empowering scientists with faster, more reproducible insights Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. "Our Living Image Synergy AI software marks a significant leap forward in p

    9/29/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity upgraded by UBS with a new price target

    UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

    5/1/25 7:42:49 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by Bernstein with a new price target

    Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

    1/10/25 8:41:17 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity upgraded by BofA Securities with a new price target

    BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

    12/13/24 8:43:02 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Gonzales Anita covered exercise/tax liability with 149 shares, decreasing direct ownership by 3% to 4,340 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:09 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Krakowiak Maxwell covered exercise/tax liability with 559 shares, decreasing direct ownership by 4% to 12,217 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:14 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Michas Alexis P sold $44,505 worth of shares (500 units at $89.01) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/28/25 4:05:04 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    SEC Filings

    View All

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    8/5/25 4:10:32 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    7/28/25 7:12:47 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 11-K filed by Revvity Inc.

    11-K - REVVITY, INC. (0000031791) (Filer)

    6/20/25 2:18:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity to Hold Earnings Call on Monday, October 27, 2025

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workfl

    10/6/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

    Facility designed to advance the next generation of imaging systems Revvity, Inc. (NYSE:RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will hel

    9/2/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials